Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data
- PMID: 11384787
- DOI: 10.1016/s0197-2456(01)00110-6
Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data
Abstract
Stinnett and Mullahy recently introduced the concept of net health benefit as an alternative to cost-effectiveness ratios for the statistical analysis of patient-level data on the costs and health effects of competing interventions. Net health benefit addresses a number of problems associated with cost-effectiveness ratios by assuming a value for the willingness-to-pay for a unit of effectiveness. We extend the concept of net health benefit to demonstrate that standard statistical procedures can be used for the analysis, power, and sample size determinations of cost-effectiveness data. We also show that by varying the value of the willingness-to-pay, the point estimate and confidence interval for the incremental cost-effectiveness ratio can be determined. An example is provided.
Similar articles
-
Cost-effectiveness analysis when the WTA is greater than the WTP.Stat Med. 2001 Nov 15;20(21):3251-9. doi: 10.1002/sim.1018. Stat Med. 2001. PMID: 11746316
-
Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.Health Econ. 1999 May;8(3):203-11. doi: 10.1002/(sici)1099-1050(199905)8:3<203::aid-hec413>3.0.co;2-7. Health Econ. 1999. PMID: 10348415
-
Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.BMC Health Serv Res. 2018 Jul 31;18(1):590. doi: 10.1186/s12913-018-3356-7. BMC Health Serv Res. 2018. PMID: 30064428 Free PMC article.
-
Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pharmacoeconomics. 2017 Apr;35(4):415-424. doi: 10.1007/s40273-016-0457-1. Pharmacoeconomics. 2017. PMID: 27770303 Review.
-
Incremental net benefit in the analysis of economic data from clinical trials, with application to the CADET-Hp trial.Eur J Gastroenterol Hepatol. 2004 Jun;16(6):543-9. doi: 10.1097/00042737-200406000-00006. Eur J Gastroenterol Hepatol. 2004. PMID: 15167155 Review.
Cited by
-
Joint distribution approaches to simultaneously quantifying benefit and risk.BMC Med Res Methodol. 2006 Oct 12;6:48. doi: 10.1186/1471-2288-6-48. BMC Med Res Methodol. 2006. PMID: 17038184 Free PMC article.
-
Electrical dry needling versus conventional physiotherapy in the treatment of active and latent myofascial trigger points in patients with nonspecific chronic low back pain.Trials. 2022 Mar 28;23(1):238. doi: 10.1186/s13063-022-06179-y. Trials. 2022. PMID: 35346331 Free PMC article. Clinical Trial.
-
Cognitive behavioral therapy for insomnia in stable heart failure: Protocol for a randomized controlled trial.Contemp Clin Trials. 2017 Apr;55:16-23. doi: 10.1016/j.cct.2017.01.009. Epub 2017 Jan 31. Contemp Clin Trials. 2017. PMID: 28159703 Free PMC article. Clinical Trial.
-
Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care.BMJ. 2004 Mar 27;328(7442):747. doi: 10.1136/bmj.38033.896505.EB. Epub 2004 Mar 15. BMJ. 2004. PMID: 15023830 Free PMC article. Clinical Trial.
-
Cost-utility analysis of a dance intervention for adolescent girls with internalizing problems.Cost Eff Resour Alloc. 2013 Feb 20;11(1):4. doi: 10.1186/1478-7547-11-4. Cost Eff Resour Alloc. 2013. PMID: 23425608 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical